Cartesian Therapeutics, Inc. (RNAC)
D
Pipeline Grade
Financial Position (from SEC Filings)
$120.4M
Cash & Equivalents
$22.1M
Quarterly Burn Rate
16 mo
Est. Cash Runway
$278M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-11-30 | Phase3 Readout | — |
| 2026-12-01 | Phase2 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06799247 | Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | PHASE3 | Recruiting | 100 |
| NCT06038474 | Descartes-08 for Patients With Systemic Lupus Erythematosus | PHASE2 | Active Not Recruiting | 6 |
| NCT07391605 | Descartes-08 in Autoantibody Myositis | PHASE2 | Recruiting | 60 |
| NCT07089121 | Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders | PHASE2 | Recruiting | 50 |
| NCT04146051 | Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) | PHASE2 | Active Not Recruiting | 30 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.